Miglustat product-specific bioequivalence guidance
Table of contents
This document provides product-specific guidance on the demonstration of the bioequivalence of miglustat. Please note that no comments have been received for this guideline during the public consultation period.
Keywords: Bioequivalence, generics, miglustat
Abbreviations:
- BCS Classification: Biopharmaceutics Classification System
- AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
- AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
- Cmax: maximum plasma concentration
-
List item
Miglustat hard capsules 100 mg product-specific bioequivalence guidance (PDF/77.66 KB)
Adopted
First published: 25/05/2016
Last updated: 25/05/2016
Legal effective date: 01/06/2015
EMA/CHMP/675841/2014 -
List item
Draft miglustat product-specific bioequivalence guidance (PDF/80.7 KB)
Draft: consultation closed
First published: 15/11/2013
Last updated: 15/11/2013
Consultation dates: 15/11/2013 to 15/02/2014
CHMP/PKWP/EMA/422796/2013